Building an Efficient R&D Chemo-Centric Data Repository System that Leads to Knowledge Discovery Presentations presentations Aug 18, 2018 20180818 /content/dam/pmiscience/default-fallback-thumbnails/publication/fallback4.png
      Presentations

      Building an Efficient R&D Chemo-Centric Data Repository System that Leads to Knowledge Discovery

      Pospisil, P.; Martin, E.; Castellon, A.; Bentley, M.
      Conference date
      Aug 18, 2018
      Conference name
      International Drug Discovery Science and Technology Conference (IDDST) 2018
      Link to more information
      Topic
      Summary

      No abstract available.

      Related Publications

      Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)

      Clinical

      Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)

      Clinical

      Use of capillary aerosol generator in continuous production of controlled aerosol for non-clinical studies

      Aerosol Physics Pre-clinical Toxicology

      Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters

      Pre-clinical Toxicology

      Quantification and mapping of alkylation in the human genome reveal single nucleotide resolution precursors of mutational signatures

      Pre-clinical Toxicology

      Meta-analysis of the effects of smoking and smoking cessation on triglyceride levels

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.